That's not what Cyrus said. 1:32: 44: So what d
Post# of 144789
![](/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
1:32: 44: So what do we expect in 2023? So our largest priority is the removal of the clinical hold in HIV. This is essentially a gating step for us to be able to get back to normal operations as a company and do what biotech companies do, which is advanced therapeutics and try to bring them to market.
1:33:10: Following the lift of the clinical hold, we expect financing to fund operations and to achieve this value inflection point that I've just alluded to. We intend on initiating a new NASH trial. We would like to commit to an investment in and advance longer-acting CCR5 molecules, as this is potentially the future of at least certainly HIV therapy, as Dr. Sacha presented.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)